NO316624B1 - 4-mercaptopyrrolidinderivater, anvendelse og fremstilling derav, samt farmasoytisk preparat - Google Patents

4-mercaptopyrrolidinderivater, anvendelse og fremstilling derav, samt farmasoytisk preparat Download PDF

Info

Publication number
NO316624B1
NO316624B1 NO19980467A NO980467A NO316624B1 NO 316624 B1 NO316624 B1 NO 316624B1 NO 19980467 A NO19980467 A NO 19980467A NO 980467 A NO980467 A NO 980467A NO 316624 B1 NO316624 B1 NO 316624B1
Authority
NO
Norway
Prior art keywords
compound
amino
ylmethyl
mmol
cdcl
Prior art date
Application number
NO19980467A
Other languages
English (en)
Norwegian (no)
Other versions
NO980467D0 (no
NO980467L (no
Inventor
David Huw Davies
Francis Thomas Boyle
James Michael Wardleworth
Zbigniew Stanley Matusiak
Peter Wedderburn Kenny
Peter Beverly Scholes
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO980467D0 publication Critical patent/NO980467D0/no
Publication of NO980467L publication Critical patent/NO980467L/no
Publication of NO316624B1 publication Critical patent/NO316624B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
NO19980467A 1995-08-04 1998-02-03 4-mercaptopyrrolidinderivater, anvendelse og fremstilling derav, samt farmasoytisk preparat NO316624B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515975.2A GB9515975D0 (en) 1995-08-04 1995-08-04 Chemical compounds
PCT/GB1996/001810 WO1997006138A1 (fr) 1995-08-04 1996-07-30 Derives de 4-mercaptopyrrolidine en tant qu'inhibiteurs de farnesyle transferase

Publications (3)

Publication Number Publication Date
NO980467D0 NO980467D0 (no) 1998-02-03
NO980467L NO980467L (no) 1998-04-03
NO316624B1 true NO316624B1 (no) 2004-03-15

Family

ID=10778742

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19980467A NO316624B1 (no) 1995-08-04 1998-02-03 4-mercaptopyrrolidinderivater, anvendelse og fremstilling derav, samt farmasoytisk preparat
NO20024950A NO20024950D0 (no) 1995-08-04 2002-10-15 4-Merkaptopyrrolidinderivater som farnesyltransferaseinhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20024950A NO20024950D0 (no) 1995-08-04 2002-10-15 4-Merkaptopyrrolidinderivater som farnesyltransferaseinhibitorer

Country Status (23)

Country Link
US (2) US6232338B1 (fr)
EP (1) EP0842151A1 (fr)
JP (1) JPH11510178A (fr)
KR (1) KR100502770B1 (fr)
CN (2) CN1101380C (fr)
AU (1) AU720353B2 (fr)
BR (1) BR9609701A (fr)
CA (1) CA2226671C (fr)
CZ (1) CZ293694B6 (fr)
GB (1) GB9515975D0 (fr)
HU (1) HUP9802857A3 (fr)
IL (1) IL123155A0 (fr)
MX (1) MX9800946A (fr)
MY (1) MY141457A (fr)
NO (2) NO316624B1 (fr)
NZ (1) NZ313696A (fr)
PL (1) PL190873B1 (fr)
RU (1) RU2191773C2 (fr)
SK (1) SK14598A3 (fr)
TR (2) TR199800147T1 (fr)
TW (1) TW345575B (fr)
WO (1) WO1997006138A1 (fr)
ZA (1) ZA966610B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310095B1 (en) 1995-11-06 2001-10-30 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6221865B1 (en) 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6204293B1 (en) 1995-11-06 2001-03-20 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6693123B2 (en) 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
EP0923545A1 (fr) * 1996-08-17 1999-06-23 Zeneca Limited 3-mercaptopyrrolidines comme inhibiteurs de la farnesyle-proteine transferase
ATE546139T1 (de) * 1997-05-07 2012-03-15 Univ Pittsburgh Isoprentransferase proteine inhibitoren
WO1999020612A1 (fr) 1997-10-22 1999-04-29 Astrazeneca Uk Limited Derives imidazoles et leur utilisation comme inhibiteurs de la farnesyle-transferase
WO1999020611A1 (fr) 1997-10-22 1999-04-29 Zeneca Limited Derives d'imidazole et leur utilisation comme inhibiteurs de la farnesyle-proteine transferase
WO1999041235A1 (fr) * 1998-02-10 1999-08-19 Astrazeneca Uk Limited Inhibiteurs de la farnesyle transferase
GB9930317D0 (en) * 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
GB9930318D0 (en) * 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
WO2004022097A1 (fr) * 2002-09-05 2004-03-18 Medimmune, Inc. Methodes de prevention ou de traitement de malignites cellulaires par administration d'antagonistes de cd2
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660186B1 (fr) 2003-08-18 2013-12-25 MedImmune, LLC Humanisation d'anticorps
SI1667991T1 (sl) 2003-09-16 2008-10-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji tirozin kinaze
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド シヌクレイノパチーを治療する方法
EP1744751A4 (fr) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Traitement des synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089515A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes de traitement des synucleinopathies
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006102095A2 (fr) 2005-03-18 2006-09-28 Medimmune, Inc. Rearrangement de l'infrastructure d'anticorps
WO2007002543A2 (fr) 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
WO2007092285A2 (fr) * 2006-02-02 2007-08-16 Link Medicine Corporation Traitement de synucléinopathies
EP2292663B1 (fr) 2006-08-28 2013-10-02 Kyowa Hakko Kirin Co., Ltd. Anticorps antagonistes monoclonaux humains specifiques á LIGHT humaine
AU2008232902B2 (en) 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
CN101376656A (zh) * 2007-08-30 2009-03-04 山东轩竹医药科技有限公司 培南衍生物
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
WO2009151683A2 (fr) * 2008-03-12 2009-12-17 Link Medicine Corporation Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CN102448458B (zh) 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
EP3763740A1 (fr) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
KR20130136550A (ko) * 2011-03-30 2013-12-12 캐논 가부시끼가이샤 중합성 단량체, 고분자 화합물, 고분자 화합물을 함유하는 하전 제어제 및, 하전 제어제를 함유하는 현상제 담지체 및 토너
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2014059028A1 (fr) 2012-10-09 2014-04-17 Igenica, Inc. Anticorps anti-c16orf54 et leurs méthodes d'utilisation
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗C10orf54抗体およびその使用方法
DK3041507T3 (da) 2013-08-26 2021-07-26 Biontech Res And Development Inc Nukleinsyrer, der koder for humane antistoffer mod sialyl-lewis a
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102226248B1 (ko) 2014-06-04 2021-03-12 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 gd2에 대한 사람 단클론 항체
WO2016094837A2 (fr) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anticorps anti-c10orf54 et leurs utilisations
ES2937020T3 (es) 2015-03-03 2023-03-23 Kymab Ltd Anticuerpos, usos y métodos
WO2017011323A1 (fr) 2015-07-10 2017-01-19 University Of Maryland, Baltimore Inhibiteurs à petites molécules de l'oncoprotéine mcl-1 et leurs utilisations
EP3909983A1 (fr) 2015-12-02 2021-11-17 STCube & Co. Inc. Anticorps et molécules se liant de manière immunospécifique à btn1a1 et leurs utilisations thérapeutiques
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP2020522512A (ja) 2017-05-31 2020-07-30 ストキューブ アンド シーオー., インコーポレイテッド Btn1a1に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー., インコーポレイテッド Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
EP3694889A1 (fr) 2017-10-13 2020-08-19 Boehringer Ingelheim International GmbH Anticorps humains dirigés contre l'antigène thomsen-nouveau (tn)
US20230243836A1 (en) 2018-07-20 2023-08-03 Pierre Fabre Medicament Receptor for vista
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (fr) 1983-05-09 1991-05-07 Makoto Sunagawa COMPOSE DE .beta.-LACTAM ET PROCEDE DE PRODUCTION
JPS60233076A (ja) 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
DE3579888D1 (de) 1984-11-08 1990-10-31 Sumitomo Pharma Carbapenemverbindungen und deren herstellung.
KR880006244A (ko) 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
GB8921635D0 (en) 1989-09-25 1989-11-08 Fujisawa Pharmaceutical Co 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
CA2036163C (fr) 1990-02-14 2001-06-19 Makoto Sunagawa Nouveaux composes de beta-lactame et leur production
NZ237191A (en) 1990-02-23 1992-12-23 Sankyo Co 2-((substituted amide) substituted heterocyclylthio) carbpen-2-em derivatives and pharmaceutical compositions
GB9107363D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5185248A (en) 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
JPH0578360A (ja) 1991-01-31 1993-03-30 Banyu Pharmaceut Co Ltd 2−[2−(スルフアモイルアルキル)ピロリジニルチオカルバペネム誘導体
GB9107342D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
GB9107341D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
NO302475B1 (no) 1991-06-04 1998-03-09 Sankyo Co 1-metylkarbapenemderivater og farmasöytisk preparat inneholdende disse
JPH04368386A (ja) 1991-06-18 1992-12-21 Sankyo Co Ltd 1−メチルカルバペネム−3−カルボン酸の製造法
US5360798A (en) 1991-07-04 1994-11-01 Shionogi Seiyaku Kabushiki Kaisha Aminooxypyrrolidinylthiocarbapenem compounds
EP0537007B1 (fr) 1991-10-11 1995-08-09 E.R. SQUIBB & SONS, INC. Utilisation d'inhibiteurs de farnésyl-protéine transferase pour la fabrication d'un médicament pour bloquer les transformations néoplastiques de cellules provoquées par des oncogènes ras
JPH05239058A (ja) 1991-12-17 1993-09-17 Fujisawa Pharmaceut Co Ltd 3−ピロリジニルチオ−1−アザビシクロ[3.2.0ヘプト−2−エン−2−カルボン酸化合物
GB9202298D0 (en) 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
HU218676B (hu) 1992-03-11 2000-10-28 Sankyo Co. Ltd. Antimikrobiális karbapenemszármazékok, ilyen vegyületeket tartalmazó gyógyászati készítmények és eljárás ezek előállítására
GB9304156D0 (en) 1992-03-26 1993-04-21 Zeneca Ltd Antibiotic compounds
CA2091309A1 (fr) 1992-03-26 1993-09-27 Frederic H. Jung Composes antibiotiques
CA2117899A1 (fr) 1992-04-13 1993-10-28 Masayoshi Murata 3-pyrrolidinylthio-carbapenemes substitues utilises comme agents antimicrobiens
EP0581502B1 (fr) 1992-07-21 1998-10-21 Zeneca Limited Dérivés de carbapénème antibiotiques
EP0581501B1 (fr) 1992-07-21 1998-09-09 Zeneca Limited Dérivés de carbapénème antibiotiques
CA2099818A1 (fr) 1992-07-21 1994-01-22 Frederic H. Jung Composes antibiotiques
EP0590885B1 (fr) 1992-09-28 2000-03-15 Zeneca Limited Dérivés de carbapénème antibiotiques
CA2106330A1 (fr) 1992-10-07 1994-04-08 Patrice J. Siret Composes antibiotiques
CA2118985A1 (fr) 1993-04-02 1994-10-03 Dinesh V. Patel Inhibiteurs heterocycliques de la farnesyl proteine transferase
WO1995000497A1 (fr) 1993-06-18 1995-01-05 Merck & Co., Inc. Inhibiteurs de farnesyle-proteine transferase
JPH09504277A (ja) * 1993-09-30 1997-04-28 メルク エンド カンパニー インコーポレーテッド ファルネシル−タンパク質トランスフェラーゼの阻害剤
US5468733A (en) * 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2122795A (en) 1994-03-15 1995-10-03 Eisai Co. Ltd. Isoprenyl transferase inhibitors
CA2155448A1 (fr) * 1994-08-11 1996-02-12 Katerina Leftheris Inhibiteurs de la farnesyl-proteine-transferase
US5571835A (en) 1994-09-29 1996-11-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CN1064682C (zh) 1995-07-31 2001-04-18 盐野义制药株式会社 具有磷脂酶a2抑制活性的吡咯烷衍生物
JP3115285B2 (ja) 1999-04-27 2000-12-04 徳光 中ノ瀬 合成樹脂体を利用した水上施設

Also Published As

Publication number Publication date
JPH11510178A (ja) 1999-09-07
CN1377647A (zh) 2002-11-06
MY141457A (en) 2010-04-30
IL123155A0 (en) 1998-09-24
CN1197453A (zh) 1998-10-28
AU6622396A (en) 1997-03-05
US6232338B1 (en) 2001-05-15
GB9515975D0 (en) 1995-10-04
TR200101884T2 (tr) 2002-06-21
NO20024950L (no) 1998-04-03
NO20024950D0 (no) 2002-10-15
CZ293694B6 (cs) 2004-07-14
RU2191773C2 (ru) 2002-10-27
PL190873B1 (pl) 2006-02-28
PL324819A1 (en) 1998-06-22
CZ30998A3 (cs) 1998-06-17
EP0842151A1 (fr) 1998-05-20
WO1997006138A1 (fr) 1997-02-20
TR199800147T1 (xx) 1998-04-21
US6541491B1 (en) 2003-04-01
HUP9802857A3 (en) 1999-05-28
NZ313696A (en) 2000-01-28
HUP9802857A2 (hu) 1999-04-28
BR9609701A (pt) 1999-03-23
NO980467D0 (no) 1998-02-03
NO980467L (no) 1998-04-03
CA2226671A1 (fr) 1997-02-20
KR100502770B1 (ko) 2007-03-15
CN1101380C (zh) 2003-02-12
SK14598A3 (en) 1998-09-09
CA2226671C (fr) 2005-04-05
AU720353B2 (en) 2000-06-01
ZA966610B (en) 1997-02-04
MX9800946A (es) 1998-04-30
KR19990036110A (ko) 1999-05-25
TW345575B (en) 1998-11-21

Similar Documents

Publication Publication Date Title
NO316624B1 (no) 4-mercaptopyrrolidinderivater, anvendelse og fremstilling derav, samt farmasoytisk preparat
ES2268793T3 (es) Anilidas sustituidas.
AU2002321062B2 (en) N-formyl hydroxylamine compounds as inhibitors of PDF
US20050209217A1 (en) 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors
KR100956990B1 (ko) 알킬에테르유도체 또는 그 염
IE911857A1 (en) Aromatic pyrrolidine and thiazolidine amides
JPH021491A (ja) 3―ピロリジニルチオ―1―アザビシクロ[3.2.0]ヘプト―2―エン―2―カルボン酸化合物
EP1856096A2 (fr) Derives de phenylglycinamide utilises comme anticoagulants
EA021367B1 (ru) Производное пиридин-3-карбоксамида
AU2002321062A1 (en) N-formyl hydroxylamine compounds as inhibitors of PDF
NO333800B1 (no) Arylamidin-derivat eller salt derav samt antisoppmiddel inneholdende samme
CA2724003A1 (fr) Nouveaux n-(2-amino-phenyl)-acrylamides
CA2186623A1 (fr) Compose d'acide benzo?que et son utilisation comme medicament
RU2162088C2 (ru) 1-метилкарбапенем или его фармакологически приемлемые соли, композиция, способ предупреждения или лечения бактериальных инфекций
RU2259997C2 (ru) Ингибиторы фарнезилтрансферазы
KR20230154231A (ko) 클로스트리디움 디피실레의 치료에 유용한 디아제핀 유도체
CA2388669A1 (fr) Inhibiteurs de farnesyl proteine transferase
JPH06116268A (ja) 3−置換オキシ−1−アザビシクロ[3.2.0]ヘプト−2−エン−2−カルボン酸化合物